Reflecting on the three Year Anniversary of the Approval of Ibrutinib in the USA
I realized this week that Feb. 12 was the 3rd anniversary of the approval of ibrutinib in the USA that changed the whole treatment landscape in CLL, so I thought I would reflect on all the progress that has taken place in the treatment of our disease during this time frame and all the issues that still remain. You can read my thoughts and share your own here: http://cllsociety.org/2017/02/reflections-three-year-anniversary/
What a wild and wonderful three years it has been- but we are not over the finish line quite yet.
Stay strong.
We are all in this together.
Brian
http://cllsociety.org
What a wild and wonderful three years it has been- but we are not over the finish line quite yet.
Stay strong.
We are all in this together.
Brian
http://cllsociety.org
Labels: Chronic lymphocytic leukemia, CLL, ibrutinib
posted by Brian Koffman at
10:51 PM
1 Comments:
We are all thankful for Ibrutinib. Without it, many of us would not be here. The problem lies with cost. The real problem with health care cost in this country is not the ACA, or insurance companies, but the high cost of drugs and medical providers. Until the underlying costs are brought under control all this blather about "insurance" is nothing but moving the deck chairs on a very expensive ship.
Post a Comment
Subscribe to Post Comments [Atom]
<< Home